TGArchive
·1 хв читання · 38 слів·👁 8.1K12

Singapore’s KPB Biosciences fails in bid to unfreeze assets in US$830 million Novo Nordisk legal battle

The Danish drugmaker alleges that KPB misled it about its drug for hypertension and kidney disease, which has since been proven ineffective.

https://bt.sg/tP2n

Відкрити в Telegram
Повернутись до каналу